Ulcerative Colitis Clinical Trial
Official title:
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
Improved methods are needed to monitor patients with inflammatory bowel disease. Telemedicine
has shown promise in patients with other chronic diseases; pilot testing in our patients with
inflammatory bowel disease demonstrated that the technology was feasible and improved
clinical outcomes.
The telemedicine system for patients with inflammatory bowel disease (Tele-IBD) should
improve outcomes for patients, improve access to care in areas with limited resources, and
decrease health care costs.
Introduction: Inflammatory bowel disease (IBD) is a chronic condition that results in
debilitating symptoms. Although effective treatments exist, inadequate monitoring of symptoms
and side effects, nonadherence, and poor patient knowledge are barriers to success.
Telemedicine has been used in other chronic diseases to improve outcomes; pilot testing of
telemedicine demonstrated that it is feasible and accepted in IBD. Our preliminary results
from a randomized trial in participants with ulcerative colitis showed significant
improvements in quality of life from baseline to one year in the telemanagement group.
Study Design: Telemedicine for Patients with Inflammatory Bowel Disease (Tele-IBD) is a
12-month, multicenter, randomized, controlled trial to assess the impact of Tele-IBD compared
to standard care in participants with IBD. The aims of the study are to: (1) assess disease
activity in participants with IBD using Tele-IBD compared to participants using standard
care, (2) assess quality of life in participants with IBD using Tele-IBD compared to
participants using standard care, and (3) estimate differences of person-level rates of
utilization of health care resources in participants with IBD using Tele-IBD compared to
participants using standard care.
Methods: Tele-IBD consists of a web-portal and a weight scale. Participants answer questions
about IBD symptoms, side effects and adherence using their home PC or a laptop with wireless
Internet access provided to them for the study. A series of educational topics is
administered via video messaging every 2-3 weeks. Tele-IBD participants complete self-testing
weekly or every other week; the results are immediately available on the web-portal for
review. Based on the responses, alerts and action plans are created for each participant. A
nurse care coordinator consults the participant's medical provider for management changes if
necessary. IBD patients evaluated at the University of Maryland, Baltimore, University of
Pittsburgh, and Vanderbilt University will be invited to participate. Interested patients
will be randomized in a 1:1:1 fashion to receive Tele-IBD weekly, Tele-IBD every other week,
or standard care. Disease activity, quality of life, medical adherence, and utilization of
health care resources will be assessed every 6 months for one year. In addition, provider
interactions with patients in all three arms will be monitored and recorded.
Expected Findings: Tele-IBD will decrease disease activity and improve quality of life
through improved adherence and monitoring of symptoms, earlier and more effective
implementation of therapy, more frequent patient-provider interactions, and improved patient
self-management. Better control of IBD will result in decreased utilization of health care
resources.
Significance: If Tele-IBD improves outcomes, it is likely to be used to improve IBD care, to
contain health care costs, to increase access to care, and to improve adherence with
physician performance measures.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
| Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
| Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
| Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
| Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
| Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
| Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
| Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
| Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
| Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
| Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
| Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
| Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
| Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
| Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |